MRD workshop at AMP 2025 on tumor-agnostic testing and standardization challenges

This expert panel discussion that took place at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, explores current advances and future challenges in minimal residual disease (MRD) testing using liquid biopsy technologies. Featuring leaders from academia, industry, and clinical diagnostics, the conversation highlights progress in detecting circulating tumor DNA at extremely low levels, alongside the need for improved sensitivity, specificity, and standardization.

The panel examines emerging approaches such as tumor‑naive MRD testing, multi‑omics integration, including epigenetics and fragmentomics, and the growing role of AI and large datasets in improving assay performance. Key topics also include clinical validation, regulatory challenges, and the potential of MRD testing to enable earlier intervention and more personalized cancer treatment.